Adherence to immunomodulatory drugs in patients with multiple myeloma.
BACKGROUND:Immunomodulatory drugs (thalidomide, lenalidomide and pomalidomide; IMID) are widely used in the treatment of multiple myeloma patients. To date, few data are available on IMID adherence in multiple myeloma patients. The aim of our study was to evaluate IMID adherence and to compare two i...
Main Authors: | Amélie Cransac, Serge Aho, Marie-Lorraine Chretien, Maurice Giroud, Denis Caillot, Mathieu Boulin |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2019-01-01
|
Series: | PLoS ONE |
Online Access: | https://doi.org/10.1371/journal.pone.0214446 |
Similar Items
-
Central neurotoxicity of immunomodulatory drugs in multiple myeloma
by: Urmeel H. Patel, et al.
Published: (2015-03-01) -
Next-generation immunomodulatory drugs in multiple myeloma
by: Anna Suska, et al.
Published: (2019-12-01) -
Immunomodulatory drugs (IMiDs) in multiple myeloma: mechanism of action and clinical implications
by: Xu, Mengni
Published: (2017) -
Immunomodulatory Compounds (Imids®) in the Treatment of Multiple Myeloma
by: Gordan Srkalovic, et al.
Published: (2009-10-01) -
Genome-Wide Circular RNA Expression Patterns Reflect Resistance to Immunomodulatory Drugs in Multiple Myeloma Cells
by: Theresa Jakobsen, et al.
Published: (2021-01-01)